摘要
新型钙增敏剂左西孟旦(LS)通过增加细胞收缩蛋白对Ca2+的敏感性及K+通道的开放而兼有强心和扩血管作用。LS强心时不增加心肌耗氧,因此适用于心力衰竭、心肌缺血及心源性休克患者的强心治疗。最新研究表明,LS具有减轻炎症反应、抑制细胞凋亡等作用,提示LS在感染性休克强心治疗可能有优势。本文主要就LS新近的研究进展作一综述。
Levosimendan （LS） is a new calcium sensitizer with inotropic and vasodilatory actions mediated by the sensitization of contractile proteins to calcium and opening of potassium channels. LS does not increase myocardial oxygen demand, therefore it is suitable for the cardiotonic support in patients with heart failure, myocardial ischemia, and cardiogenic shock. Updated studies suggest that LS has anti-inflammatory and anti-apoptotie effects, which implies that LS possesses advantages in the cardiotonic treatment of septic shock. This review summarizes the recent researches of LS.
出处
《药学与临床研究》
2010年第5期458-461,共4页
Pharmaceutical and Clinical Research
基金
江苏省六大人才高峰课题
